» Articles » PMID: 15542787

The Role of Nuclear Y-box Binding Protein 1 As a Global Marker in Drug Resistance

Overview
Journal Mol Cancer Ther
Date 2004 Nov 16
PMID 15542787
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Gene expression can be regulated by nuclear factors at the transcriptional level. Many such factors regulate MDR1 gene expression, but what are the sequence elements and transcription factors that control the basal and inducible expression of this gene? The general principles through which transcription factors participate in drug resistance are now beginning to be understood. Here, we review the factors involved in the transcriptional regulation of the MDR1 gene. In particular, we focus on the transcription factor Y-box binding protein 1 and discuss the possible links between Y-box binding protein 1 expression and drug resistance in cancer, which are mediated by the transmembrane P-glycoprotein or non-P-glycoprotein.

Citing Articles

Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy.

Dheeraj A, Marques F, Tailor D, Bermudez A, Resendez A, Pandrala M Cell Rep Med. 2024; 5(5):101552.

PMID: 38729158 PMC: 11148772. DOI: 10.1016/j.xcrm.2024.101552.


Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.

Quan C, Wu Z, Xiong J, Li M, Fu Y, Su J Exp Hematol Oncol. 2023; 12(1):100.

PMID: 38037159 PMC: 10687910. DOI: 10.1186/s40164-023-00462-7.


FBL promotes cancer cell resistance to DNA damage and BRCA1 transcription via YBX1.

Sun X, Gao C, Xu X, Li M, Zhao X, Wang Y EMBO Rep. 2023; 24(9):e56230.

PMID: 37489617 PMC: 10481664. DOI: 10.15252/embr.202256230.


YB-1 as an Oncoprotein: Functions, Regulation, Post-Translational Modifications, and Targeted Therapy.

Yin Q, Zheng M, Luo Q, Jiang D, Zhang H, Chen C Cells. 2022; 11(7).

PMID: 35406781 PMC: 8997642. DOI: 10.3390/cells11071217.


An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.

Ushijima M, Shiota M, Matsumoto T, Kashiwagi E, Inokuchi J, Eto M Cancer Sci. 2022; 113(5):1731-1738.

PMID: 35118769 PMC: 9128173. DOI: 10.1111/cas.15280.